Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

作者：Shaji Kumar, Jesús G. Berdeja, Rubén Niesvizky, Sagar Lonial, Jacob P. Laubach, Mehdi Hamadani, A. Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio, Jonathan L. Kaufman, Deborah Berg, Eileen Liao, Alessandra Di Bacco, Jose Estevam, Neeraj Gupta, Ai-Min Hui, S. Vincent Rajkumar, Paul G. Richardson · 发表于：The Lancet Oncology · 年份：2014 · DOI：10.1016/s1470-2045(14)71125-8 · 被引用次数：265 · 研究领域：Multiple Myeloma Research and Treatments、Ubiquitin and proteasome pathways、Cancer Treatment and Pharmacology